ERBB2 and cancer: Reverse transcription polymerase chain reaction (RT-PCR)-based tests such as 21-gene assay and oncotype DX have revealed that expression levels of ER, PR, and HER2 mRNA are associated with cancer progression and adverse patient outcomes.